Md. company to study cancer medicine feasibility

Published on NewsOK Modified: December 27, 2012 at 9:55 am •  Published: December 27, 2012

ROCKVILLE, Md. (AP) — A Rockville company will study the feasibility of a new cancer medicine with the large pharmaceutical company AstraZeneca.

CytImmune Sciences Inc. and AstraZeneca made the announcement on Thursday.

The two companies will work together to see whether they can transmit cancer drugs on extremely small gold particles.

CytImmune works in developing nanomedicine, which uses tiny particles of gold to carry cancer therapies directly to the site of the disease. The company says gold nanoparticles have been used safely since the 1930s to treat patients with rheumatoid arthritis.

Dr. Lawrence Tamarkin, CytImmune's CEO, says the partnership aims to combine CytImmune's nanotechnology research with AstraZeneca's oncology compound to create a cancer therapy that may be widely applicable to solid tumors.

Trending Now


  1. 1
    White House stands by claim that border security is stronger than ever
  2. 2
    Who is Alix Tichelman, and why was she at another high-profile businessman's fatal drug overdose?
  3. 3
    News 9: Former longtime OKC radio DJ dies Thursday
  4. 4
    KFOR: Detectives stumble upon rare extinct animals at Oklahoma ranch
  5. 5
    KOCO: Family seeks help finding Lennie, their missing leopard tortoise
+ show more